Literature DB >> 11498211

Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey.

F Mostashari1, M L Bunning, P T Kitsutani, D A Singer, D Nash, M J Cooper, N Katz, K A Liljebjelke, B J Biggerstaff, A D Fine, M C Layton, S M Mullin, A J Johnson, D A Martin, E B Hayes, G L Campbell.   

Abstract

BACKGROUND: In the summer of 1999, West Nile virus was recognised in the western hemisphere for the first time when it caused an epidemic of encephalitis and meningitis in the metropolitan area of New York City, NY, USA. Intensive hospital-based surveillance identified 59 cases, including seven deaths in the region. We did a household-based seroepidemiological survey to assess more clearly the public-health impact of the epidemic, its range of illness, and risk factors associated with infection.
METHODS: We used cluster sampling to select a representative sample of households in an area of about 7.3 km(2) at the outbreak epicentre. All individuals aged 5 years or older were eligible for interviews and phlebotomy. Serum samples were tested for IgM and IgG antibodies specific for West Nile virus.
FINDINGS: 677 individuals from 459 households participated. 19 were seropositive (weighted seroprevalence 2.6% [95% CI 1.2-4.1). Six (32%) of the seropositive individuals reported a recent febrile illness compared with 70 of 648 (11%) seronegative participants (difference 21% [0-47]). A febrile syndrome with fatigue, headache, myalgia, and arthralgia was highly associated with seropositivity (prevalence ratio 7.4 [1.5-36.6]). By extrapolation from the 59 diagnosed meningoencephalitis cases, we conservatively estimated that the New York outbreak consisted of 8200 (range 3500-13000) West Nile viral infections, including about 1700 febrile infections.
INTERPRETATION: During the 1999 West Nile virus outbreak, thousands of symptomless and symptomatic West Nile viral infections probably occurred, with fewer than 1% resulting in severe neurological disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498211     DOI: 10.1016/S0140-6736(01)05480-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  208 in total

Review 1.  West Nile encephalitis.

Authors:  Tom Solomon; Mong How Ooi; David W C Beasley; Macpherson Mallewa
Journal:  BMJ       Date:  2003-04-19

Review 2.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 3.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

4.  Demographic and clinical factors associated with persistent symptoms after West Nile virus infection.

Authors:  Robert L Cook; Xiaohui Xu; Eric J Yablonsky; Nikole Sakata; Jennifer H Tripp; Rachel Hess; Paolo Piazza; Charles R Rinaldo
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

5.  Characterization of a West Nile virus isolate from a human on the Gulf Coast of Texas.

Authors:  Bruno P Granwehr; Li Li; Charles T Davis; David W C Beasley; Alan D T Barrett
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

Review 6.  Neurologic aspects of infections in international travelers.

Authors:  May H Han; Joseph R Zunt
Journal:  Neurologist       Date:  2005-01       Impact factor: 1.398

7.  Molecular typing of West Nile Virus, Dengue, and St. Louis encephalitis using multiplex sequencing.

Authors:  Thuraiayah Vinayagamoorthy; Kirk Mulatz; Michael Drebot; Roger Hodkinson
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

8.  Effect of aerial insecticide spraying on West Nile virus disease--north-central Texas, 2012.

Authors:  Duke J Ruktanonchai; Shelley Stonecipher; Nicole Lindsey; Janet McAllister; Satish K Pillai; Kalanthe Horiuchi; Mark Delorey; Brad J Biggerstaff; Tom Sidwa; James Zoretic; Roger Nasci; Marc Fischer; Susan L Hills
Journal:  Am J Trop Med Hyg       Date:  2014-04-28       Impact factor: 2.345

9.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 10.  Diagnostic Approach for Arboviral Infections in the United States.

Authors:  Anne Piantadosi; Sanjat Kanjilal
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.